[
  {
    "ts": null,
    "headline": "AFLAC Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "summary": "AFLAC Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=5d87fda1ff734ecd4531efe693d6e82b6defe9db07cdd61253e3c4623b65525e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755103620,
      "headline": "AFLAC Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "id": 136358802,
      "image": "",
      "related": "AFL",
      "source": "MarketWatch",
      "summary": "AFLAC Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=5d87fda1ff734ecd4531efe693d6e82b6defe9db07cdd61253e3c4623b65525e"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Aflac’s Q2 Earnings Call",
    "summary": "Aflac’s second quarter saw a strong positive market reaction, reflecting the company’s solid operational performance and revenue growth above Wall Street expectations. Management attributed the results largely to the success of the new Miraito cancer insurance product in Japan, which spurred a 53% increase in cancer policy sales and contributed to a 23.2% year-over-year sales rise in the region. In the U.S., momentum in group life, disability, and network dental products supported steady premium",
    "url": "https://finnhub.io/api/news?id=cd8a4f54029e2e9b0a139388e092f020df50f513e69d7cddd1d73fbb8ac95277",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057810,
      "headline": "The 5 Most Interesting Analyst Questions From Aflac’s Q2 Earnings Call",
      "id": 136328616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AFL",
      "source": "Yahoo",
      "summary": "Aflac’s second quarter saw a strong positive market reaction, reflecting the company’s solid operational performance and revenue growth above Wall Street expectations. Management attributed the results largely to the success of the new Miraito cancer insurance product in Japan, which spurred a 53% increase in cancer policy sales and contributed to a 23.2% year-over-year sales rise in the region. In the U.S., momentum in group life, disability, and network dental products supported steady premium",
      "url": "https://finnhub.io/api/news?id=cd8a4f54029e2e9b0a139388e092f020df50f513e69d7cddd1d73fbb8ac95277"
    }
  },
  {
    "ts": null,
    "headline": "AFL Q2 Deep Dive: Japan Cancer Product Launch Drives Growth, U.S. Margin Discipline Maintained",
    "summary": "Supplemental insurance provider Aflac (NYSE:AFL) announced better-than-expected revenue in Q2 CY2025, with sales up 3.5% year on year to $4.54 billion. Its non-GAAP profit of $1.73 per share was 1.4% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=25b45a593f7a4428bddd7edaa7395c4cee3b8b76f1418bf47d9ca36ddb1ff489",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057475,
      "headline": "AFL Q2 Deep Dive: Japan Cancer Product Launch Drives Growth, U.S. Margin Discipline Maintained",
      "id": 136328617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AFL",
      "source": "Yahoo",
      "summary": "Supplemental insurance provider Aflac (NYSE:AFL) announced better-than-expected revenue in Q2 CY2025, with sales up 3.5% year on year to $4.54 billion. Its non-GAAP profit of $1.73 per share was 1.4% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=25b45a593f7a4428bddd7edaa7395c4cee3b8b76f1418bf47d9ca36ddb1ff489"
    }
  }
]